SCHEDULE 13G: Nantahala Capital Partners Discloses 6.24% Passive Stake in Eagle Pharmaceuticals

Nantahala Capital Partners Limited Partnership, along with its managing members Wilmot B. Harkey and Daniel Mack, has disclosed a passive beneficial ownership of 6.241% in Eagle Pharmaceuticals, Inc.

Summary

• Nantahala Capital Partners Limited Partnership, Wilmot B. Harkey, and Daniel Mack (collectively, the "Reporting Persons") have filed a Schedule 13G.
• As of February 16, 2025, the Reporting Persons beneficially own an aggregate of 810,630 shares of Common Stock of Eagle Pharmaceuticals, Inc.
• This ownership represents 6.241% of the total outstanding shares of Eagle Pharmaceuticals, Inc.
• The Reporting Persons hold shared voting power and shared dispositive power over all 810,630 shares.
• The filing indicates a passive investment intent, stating the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While a Schedule 13G is a routine disclosure, the emergence of a new institutional investor with a significant passive stake can be viewed favorably by the market as it indicates confidence and potential liquidity.

Positives

• The disclosure of a significant stake by an institutional investor like Nantahala Capital Partners can signal increased institutional confidence or interest in Eagle Pharmaceuticals, Inc.
• The passive nature of the investment, as certified by the reporting persons, suggests that the stake is not intended for activist purposes, which can provide stability.

Future Outlook

This document does not provide any forward-looking statements or guidance regarding Eagle Pharmaceuticals, Inc.'s future performance or strategic direction, as it is solely a beneficial ownership disclosure.

Industry Context

The filing indicates a notable institutional investment in a pharmaceutical company, which is a common occurrence in the sector as investors seek opportunities in healthcare innovation and established drug portfolios. Such disclosures reflect ongoing capital allocation decisions by investment firms within the broader healthcare industry.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may be perceived positively, potentially increasing investor confidence and liquidity in the stock.

Key Dates

Keywords

Eagle Pharmaceuticals, Nantahala Capital Partners, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Pharmaceuticals, Passive Investment